Danimer Scientific, Inc.
DNMR · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13.1% | -25.4% | -6.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -84.8% | -90.5% | -85% | -78.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -218.1% | -253.4% | -181.2% | -283.5% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -253.1% | -297.1% | -266.7% | -360.3% |
| EPS | -0.18 | -0.19 | -0.26 | -0.39 |
| % Growth | 5.3% | 26.9% | 33.3% | – |
| EPS Diluted | -7.2 | -0.19 | -0.26 | -0.39 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -218.1% | -80.6% | -107.5% | -214.3% |